Full-Time

Senior Software Quality Engineer

Updated on 9/14/2026

Illumina

Illumina

5,001-10,000 employees

Develops sequencing platforms and consumables

No salary listed

Bengaluru, Karnataka, India

Remote

Occasional travel may be required; the role supports the US region through shifts, with no night shift required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Machine Learning
SAP Products
Cybersecurity
Data Modeling

Get referred to Illumina

See people who can refer or advise you

Requirements
  • At least 5 years of experience in software quality engineering or a related role within the medical device or another regulated industry.
  • Working experience with relevant industry standards and regulations, such as ISO 13485 and 21 CFR.
  • Ability to deliver quality output under some supervision and general direction.
  • Ability to operate flexibly in a fast-paced environment.
  • Ability to partner with Software Testing, System Validation, Business Owners, and other functions to drive a culture of quality.
  • Ability to identify, correct, and prevent obstacles to assuring non-product software quality.
  • Good interpersonal, verbal, and written communication skills.
  • Ability to apply Quality Engineering principles, including structured development processes and risk management.
  • Working knowledge of product development, software development life-cycle processes, and software engineering best practices.
  • Willingness to work shifts supporting the United States region; no night shift is required.
Responsibilities
  • Review and approve software validation deliverables, including User Requirements Specifications, Functional Specifications, Configuration Specifications, risk assessments, validation plans, test protocols, reports, and change control documentation, to ensure regulatory compliance.
  • Lead software assessments, classification, and categorization.
  • Ensure validation activities for non-product software follow applicable regulations, including 21 CFR 820 and 21 CFR 11, and identify opportunities for improvement.
  • Lead software risk-management activities for non-product software, including software supporting manufacturing processes such as Camstar and LIMS, and quality-system software such as SAP and ETQ.
  • Develop and conduct software-compliance training for software developers, validation engineers, software testers, and other stakeholders.
  • Provide guidance on software life-cycle process documentation, data integrity, and electronic records and electronic signatures.
  • Support data management, data modeling, and supplier-management activities when required.
  • Participate in strategic and technical discussions and risk-based decision-making.
  • Collaborate with key stakeholders to assess software criticality and complexity.
  • Support the change-control process for validated systems by performing impact assessments to determine revalidation needs.
  • Provide support and guidance for developing new technologies, including artificial intelligence and machine learning, cybersecurity, and cloud technologies, as they relate to software systems and tools.
  • Support and facilitate internal and external audits related to the non-product software domain.
Desired Qualifications
  • Quality and/or regulatory certifications such as ASQ or AAMI are preferred.
  • Occasional travel may be required.

Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Get referred to Illumina

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Illumina raised 2026 revenue guidance to $4.60 billion-$4.64 billion after Q2 strength.
  • S&P 500 inclusion on September 21, 2026 should drive passive-fund buying.
  • Clinical volume reached 78% NovaSeq X conversion, supporting recurring consumables growth.

What critics are saying

  • FTC and Fifth Circuit GRAIL litigation still threatens forced divestiture and management distraction.
  • Research consumables declined in 2026 while clinical demand carried growth, exposing narrow dependence.
  • BGI and Thermo Fisher keep pressuring sequencing pricing, risking margin compression by 2027.

What makes Illumina unique

  • NovaSeq X drives clinical sequencing workflows, with 95 placements in Q2 2026.
  • Illumina pairs sequencing, DRAGEN software, and multiomics tools into one platform.
  • The new WGS MRD research solution broadens Illumina beyond core sequencing instruments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
Sep 9th, 2026
Illumina joins S&P 500 on 21 September following 112% stock surge

Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.

Yahoo Finance
Aug 26th, 2026
Illumina beats Q2 expectations with $1.16B revenue, raises full-year guidance

Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.

GenomeWeb
Aug 14th, 2026
Illumina secures $1B credit facility with Bank of America, launches note offering

Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.

AktienSensor
Aug 12th, 2026
Illumina raises $750M with 2029 senior notes to refinance debt and lower cost of capital

Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.

PR Newswire
Jul 30th, 2026
Illumina raises 2026 guidance on strong Q2 results: $1.16B revenue, up 9.5%

Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.